The company said its Q2 2024 revenue rose to $1,004 million, up 6% as reported and 7% organically. Diluted EPS was $2.44, down 9% as reported, and rose 15% on a comparable basis, excluding the $0.56 litigation-related charge.

1. 01

   The company said its Q2 2024 revenue rose to $1,004 million, up 6% as reported and 7% organically. Diluted EPS was $2.44, down 9% as reported, and rose 15% on a comparable basis, excluding the $0.56 litigation-related charge.

2. 02

   The company said it added $61.5 million to its existing $27.5 million litigation reserve in Q2, bringing its total reserve to $89.0 million. Operating margin was 26.3%, down 510 basis points from a year earlier. Excluding that item and foreign exchange effects, it said comparable operating margin rose 110 basis points.

3. 03

   The company said CAG Diagnostics recurring revenue grew 6% as reported and 7% organically in Q2. By region, international revenue rose 8% as reported and 10% organically, while U.S. revenue grew 5% on both a reported and organic basis.

4. 04

   The company updated its full-year 2024 revenue outlook to $3,885 million to $3,945 million, and said the midpoint is down $15 million from the prior outlook of $3,895 million to $3,965 million. Its EPS outlook is now $10.31 to $10.59, down $0.56 at the midpoint from the prior $10.82 to $11.20.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the opening part of the filing body and confirmed exhibits, within a length limit. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.